SGLT2 Inhibitors Lower Hyperkalemia Risk in Patients Taking RAASi 

Researchers found that starting SGLT2 inhibitors in older patients on RAAS inhibitors reduced the risk of hyperkalemia and helped more patients stay on RAAS therapy.